16:37 , Jan 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Stroke Mouse studies suggest inhibiting signaling between RTN4R, RTN4RL2 and their ligands could help treat white matter stroke. In a mouse model of the disease, white matter levels of three negative regulators of Nogo signaling...
07:00 , Jul 17, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Nerve damage; stroke Reticulon 4 (RTN4; NOGO-A; NOGO; NOGO-B) Rat studies suggest treatment with NOGO-A inhibitors followed...
07:00 , Jun 30, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Hypertension Reticulon 4 (RTN4; NOGO-A; NOGO; NOGO-B) Studies in mice and in patient samples suggest inhibiting...
07:00 , Apr 28, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Stroke Reticulon 4 (RTN4; NOGO-A; NOGO) Studies in rats suggest that inosine...
07:00 , Sep 27, 2010 |  BioCentury  |  Emerging Company Profile

Axerion: Going beyond NOGO

While several companies are working on approaches to stimulating axonal regrowth for conditions caused or characterized by nerve damage, Axerion Therapeutics Inc. believes its NGR receptor decoys will more potently treat conditions such as acute...
07:00 , Sep 6, 2010 |  BioCentury  |  Strategy

Laying siege

sanofi-aventis Group made clear in its conference call last week that it's in no hurry to complete its proposed acquisition of Genzyme Corp. - with the obvious implication that time is on its side. If...
07:00 , Jul 1, 2010 |  BC Innovations  |  Targets & Mechanisms

Neuraminidase for spinal cord injury

Researchers at The Johns Hopkins University School of Medicine have shown that treatment with a recombinant bacterial neuraminidase can promote the recovery of motor and autonomic function in a rat model of spinal cord contusion...
07:00 , May 27, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Reticulon 4 (RTN4; NOGO-A; NOGO); myelin-associated glycoprotein (MAG); oligodendrocyte myelin glycoprotein (OMG; OMGP); reticulon...
07:00 , Apr 15, 2010 |  BC Innovations  |  Targets & Mechanisms

Axon-regenerating small molecules

Researchers at the University of Miami Miller School of Medicine have identified compounds that can overcome the two main types of signals that inhibit axon growth in a damaged CNS.1 The compounds reversed the effects...
08:00 , Nov 24, 2008 |  BC Week In Review  |  Clinical News

ATI355 regulatory update

EMEA's Committee for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for ATI355 to treat spinal cord injury (SCI). The neutralizing inhibitory Nogo-A antibody is in Phase I testing for...